PAMU
BOLT icon

Pictet Asset Management (UK)’s Bolt Biotherapeutics BOLT Stock Holding History

Pictet Asset Management (UK)’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$2.88M Sell
9,322
-349
-4% -$142K ﹤0.01% 954
2021
Q1 		$6.37M Buy
+9,671
New +$6.29M 0.01% 780

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Pictet Asset Management (UK)'s BOLT Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its Bolt Biotherapeutics (BOLT) stake by 3.6% in Q2 2021, selling an estimated $142K and leaving 9,322 shares worth $2.88M. The position accounts for ﹤0.01% of the portfolio, ranked #954.

Pictet Asset Management (UK) first reported a position in BOLT in Q1 2021 and has held it in 2 quarters since. The position peaked at $6.37M in Q1 2021. 61 funds tracked by Wall St. Rank hold BOLT as of Q2 2021.

  • Pictet Asset Management (UK) held 9,322 shares of Bolt Biotherapeutics worth $2.88M as of Q2 2021.
  • Pictet Asset Management (UK) sold 349 Bolt Biotherapeutics shares in Q2 2021, an estimated $142K.
  • Bolt Biotherapeutics made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #954 holding.
  • Pictet Asset Management (UK) first reported a position in Bolt Biotherapeutics in Q1 2021 and has held it in 2 quarters since.
  • Pictet Asset Management (UK)'s Bolt Biotherapeutics position peaked at $6.37M in Q1 2021.
  • 61 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.